# Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

> **NCT03590652** · PHASE2 · TERMINATED · sponsor: **University of California, San Diego** · enrollment: 23 (actual)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **DRUG:** Ixazomib
- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)

## Key facts

- **NCT ID:** NCT03590652
- **Lead sponsor:** University of California, San Diego
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-17
- **Primary completion:** 2025-07-02
- **Final completion:** 2025-07-02
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** The trial met its primary endpoint.
- **Last updated:** 2025-10-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03590652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03590652, "Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03590652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*